Company / Operating Cash Flow per Share
Janux Therapeutics, Inc. Operating Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.33
FY2025
5-year range
-$1.33 / -$0.72
FY2021-FY2025
Trend
-62.8%
vs FY2024
Sector context
#125 of 210
Health Care
What the data says
At $-1.33, Janux Therapeutics, Inc.'s operating cash flow per share ranks #125 of 210 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 6 years, ranging from $-4.77 in FY2020 to $-0.72 in FY2021.
Based on SEC 10-K filings.
-1.33 in FY2025.
Declined from $-1.15 to $-1.33 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#125 of 210 in Health CareTop 60% of 210This company -$1.33 Sector average $5.30
▼
-125.0% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 62.8% year-over-year.
- Ranks #125 out of 210 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.33 | -62.8% |
| FY2024 | -$0.82 | +29.1% |
| FY2023 | -$1.15 | -11.0% |
| FY2022 | -$1.04 | -43.5% |
| FY2021 | -$0.72 | +84.9% |
| FY2020 | -$4.77 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026